{"id":"recombinant-human-interleukin-11","safety":{"commonSideEffects":[{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Arrhythmias / atrial fibrillation"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4650421","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-11 is a pleiotropic cytokine that acts on bone marrow progenitor cells to promote megakaryocyte proliferation and differentiation, leading to increased platelet production. It is used to mitigate thrombocytopenia (low platelet counts) caused by myelosuppressive chemotherapy, reducing the need for platelet transfusions and allowing patients to maintain adequate platelet levels during cancer treatment.","oneSentence":"Recombinant human interleukin-11 (rhIL-11) stimulates megakaryocyte maturation and platelet production to prevent or treat chemotherapy-induced thrombocytopenia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:34.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention and treatment of chemotherapy-induced thrombocytopenia in cancer patients"}]},"trialDetails":[{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT06759636","phase":"PHASE3","title":"FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-21","conditions":"CTIT: Cancer Therapy Induced Thrombocytopenia","enrollment":88},{"nctId":"NCT05909293","phase":"NA","title":"Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-12","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05688306","phase":"","title":"To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment","status":"COMPLETED","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2020-09-02","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":3494},{"nctId":"NCT04597073","phase":"NA","title":"Measurement of Oncostatin M, Leukemia Inhibitory Factor and Interleukin-11 Levels of Patients With Periodontal Disease","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2014-03","conditions":"Chronic Periodontitis, Generalized, Gingivitis","enrollment":72},{"nctId":"NCT01663441","phase":"PHASE3","title":"A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11","status":"COMPLETED","sponsor":"Beijing Northland Biotech. Co., Ltd.","startDate":"2015-03","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":62},{"nctId":"NCT03720340","phase":"PHASE3","title":"Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-10-01","conditions":"Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT00524225","phase":"PHASE2","title":"IL-11 in Adults With Von Willebrand Disease Undergoing Surgery","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2008-02","conditions":"Von Willebrand Disease","enrollment":3},{"nctId":"NCT03823079","phase":"PHASE2","title":"Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-02-01","conditions":"Recurrent Colorectal Carcinoma, Thrombopenia","enrollment":50},{"nctId":"NCT00012298","phase":"PHASE1, PHASE2","title":"Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT00524342","phase":"PHASE2","title":"IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia","status":"COMPLETED","sponsor":"Margaret Ragni","startDate":"2008-01","conditions":"Von Willebrand Disease","enrollment":7},{"nctId":"NCT03049774","phase":"","title":"A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2017-02-28","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":2000},{"nctId":"NCT00151125","phase":"PHASE2","title":"Phase II Study of IL-11 (Neumega) in Von Willebrand Disease","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2004-07","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT01317966","phase":"","title":"Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia","status":"WITHDRAWN","sponsor":"Ming Hou","startDate":"2011-03","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":""},{"nctId":"NCT00994929","phase":"PHASE2","title":"Efficacy and Safety of IL-11 in DDAVP Unresponsive","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-01","conditions":"Hemophilia A, Von Willebrand Disease","enrollment":9},{"nctId":"NCT02281240","phase":"","title":"Hemostatic Complications in Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Hemostatic Disorders","enrollment":200},{"nctId":"NCT02344979","phase":"","title":"The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2009-05","conditions":"Thrombocytopenia","enrollment":120},{"nctId":"NCT02314273","phase":"PHASE4","title":"Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL","status":"COMPLETED","sponsor":"Shanghai Children's Medical Center","startDate":"2011-09","conditions":"Pancytopenia Due to Chemotherapy","enrollment":120},{"nctId":"NCT02241031","phase":"PHASE2, PHASE3","title":"Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2014-09","conditions":"Hematological Diseases, Thrombocytopenia","enrollment":250},{"nctId":"NCT00040521","phase":"PHASE2","title":"Study Evaluating rhIL-11 in Active Crohn's Disease","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-04","conditions":"Crohn Disease, Inflammatory Bowel Disease","enrollment":""},{"nctId":"NCT00493181","phase":"PHASE2","title":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-10","conditions":"Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia","enrollment":8},{"nctId":"NCT00004157","phase":"PHASE2","title":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2000-08","conditions":"Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer","enrollment":""},{"nctId":"NCT00038922","phase":"PHASE1","title":"Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Ulcerative Colitis, Inflammatory Bowel Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Recombinant Human Interleukin-11","genericName":"Recombinant Human Interleukin-11","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant Human Interleukin-11 is being studied in clinical trials for various conditions, including Von Willebrand Disease, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, and Follicular Lymphoma. It has been used in a Phase II study to evaluate its hemostatic efficacy in Von Willebrand Disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}